
ALX Oncology fell 34.0% from $1.47 to $0.97, behind the S&P 500's +10.2%. Its worst day was Oct 13 (−22.3%), and its low came Oct 14 at $0.89.
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
ALX Oncology shares rose 14.6%, while the S&P 500 fell 0.2%.
+14.6%, the year's best day · S&P 500 −0.2%
ALX Oncology shares rose 14.1%, while the S&P 500 rose 0.5%.
+14.1% · S&P 500 +0.5%
Story events cover the past 12 months · Times ET
ALX Oncology closed at its highest level of the year, 76.9% above where the year started.
+12.1% · S&P 500 −0.3%
EPS of $-0.37 missed the $-0.34 estimate on $0.00 revenue.
−10.2% · S&P 500 −0.5%
EPS of $-0.15 beat the $-0.16 estimate on $0.00 revenue.
+11.2% · S&P 500 +0.8%
EPS of $-0.11 beat the $-0.15 estimate on $0.00 revenue.
+9.9% · S&P 500 −0.2%
ALX Oncology closed at its lowest level of the year, 39.1% below where the year started.
−8.7% · S&P 500 −1.1%
ALX Oncology shares fell 15.4%, while the S&P 500 fell 4.4%.
−15.4% · S&P 500 −4.4%
EPS of $-0.13 beat the $-0.13 estimate on $0.00 revenue.
−3.8% · S&P 500 −1.9%
Where it ended: a close of $0.97 on Nov 18, 2026. Up next: Q4 2026 earnings on Feb 26, 2027 (EPS est. $-0.16).
Nothing in the past 12 months.
All ALXO dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ALXO and SPY from Benzinga historical bars. Not investment advice.